Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.67M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 1.84M
Average 1.44M
Income Statement
Follow revenue through to earnings.
Revenue
$884,000.00
FY 2025 · Annual
-39.2% YoYOperating Income
-$113.56M
FY 2025 · Annual
Net Income
-$103.12M
FY 2025 · Annual
Income Statement
Metric | FY 2021 Jun 2022 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.8M | 7.1M | 1.43M | 1.45M | 884K |
| Cost of Revenue | 6.18M | 5.47M | 0 | 0 | 0 |
| Gross Profit | 4.62M | 1.63M | 1.43M | (852K) | (2.37M) |
| Gross Margin | 42.8% | 23.0% | 100.0% | -58.6% | -267.8% |
| Research & Development | 2.58M | 2.6M | 21.31M | 41.64M | 84.22M |
| Selling, General & Admin | 9.43M | 14.21M | 21.06M | 26.61M | 30.23M |
| Operating Expenses | 12.01M | 17.43M | 42.38M | 92.34M | 113.56M |
| Depreciation & Amortization | 248K | 344K | 981K | 2.31M | 3.25M |
| EBITDA | (7.39M) | (14.84M) | (39.96M) | 10.46M | (100.8M) |
| EBITDA Margin | -68.5% | -208.9% | -2786.6% | 719.3% | -11402.8% |
| Operating Income | (7.39M) | (15.18M) | (40.94M) | 10.46M | (113.56M) |
| Operating Margin | -68.5% | -213.7% | -2855.0% | 719.3% | -12846.6% |
| Interest Income | 119K | 1.12M | 934K | 10.52M | 8.11M |
| Interest Expense | 119K | 0 | 84K | (48K) | 376K |
| Other Income / Expenses | 119K | 512K | 835K | (91.84M) | 9.14M |
| Income Before Tax | (7.27M) | (14.67M) | (40.11M) | (81.38M) | (104.43M) |
| Pre-Tax Margin | -67.4% | -206.5% | -2796.8% | -5596.7% | -11813.1% |
| Income Tax Expense | (119K) | 0 | (2.65M) | (2.1M) | (793K) |
| Net Income | (7.15M) | (14.67M) | (46.51M) | (79.28M) | (103.12M) |
| Net Margin | -66.3% | -206.5% | -3243.2% | -5452.5% | -11665.3% |
| EPS (Basic) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| EPS (Diluted) | (0.13) | (0.27) | (0.85) | (1.23) | (1.40) |
| 54.91M | 54.91M | 54.91M | 64.43M | 73.81M | |
| 54.91M | 54.91M | 54.91M | 64.43M | 73.81M |
CATX Earnings Waterfall · TTM
AMEX:CATX · Revenue to Net Income
Key Ratios
Analysis
$618.0K of revenue converted into -$111.1M of net income for the selected period. Gross margin is -1014.1% and net margin is -35369.8%, showing how much revenue survives after costs and taxes. EPS is $-26.44, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 |
How much revenue does CATX generate?
Perspective Therapeutics, Inc. (CATX) reported $884,000.00 of revenue in fiscal 2025.
Is CATX profitable?
Perspective Therapeutics, Inc. (CATX) reported -$103.12M of net income, with a net margin of -11665.3%.
Continue the stock analysis
Jump to another research area for this company.